Cover Image
市場調查報告書

Onyx Pharmaceuticals, Inc. : 產品平台分析

Onyx Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224722
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
Onyx Pharmaceuticals, Inc. : 產品平台分析 Onyx Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 43 Pages
簡介

Onyx Pharmaceuticals, Inc. 是開發、銷售以癌症成因之分子構造為標的的劃時代新藥之生物製藥公司。擁有激酶抑制劑及蛋白酶體抑制劑等治療腫瘤相關的二個銷售專利,德國龍頭拜耳所開發的Nexavar已通過認証為惡化型腎臟癌、無法切除的肝臟癌、局部復發或轉移、惡化、分化的甲狀腺癌治療藥。

本報告提供Onyx Pharmaceuticals, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Onyx Pharmaceuticals, Inc.的基本資料

  • Onyx Pharmaceuticals, Inc.概要
  • 主要資訊
  • 企業資料

Onyx Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Onyx Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Onyx Pharmaceuticals, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Onyx Pharmaceuticals, Inc.:藥物簡介

  • carfilzomib
  • oprozomib
  • ONX-0914
  • PR-924

Onyx Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Onyx Pharmaceuticals, Inc.:最近的開發平台趨勢

Onyx Pharmaceuticals, Inc.:暫停中的計劃

Onyx Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07486CDB

Summary

Global Markets Direct's, 'Onyx Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Onyx Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Onyx Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Onyx Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Onyx Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Onyx Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Onyx Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Onyx Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Onyx Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Onyx Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Onyx Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Onyx Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Onyx Pharmaceuticals, Inc. Snapshot
    • Onyx Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Onyx Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Onyx Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Onyx Pharmaceuticals, Inc. - Pipeline Products Glance
    • Onyx Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Onyx Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Onyx Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Onyx Pharmaceuticals, Inc. - Drug Profiles
    • carfilzomib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oprozomib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONX-0801
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Onyx Pharmaceuticals, Inc. - Pipeline Analysis
    • Onyx Pharmaceuticals, Inc. - Pipeline Products by Target
    • Onyx Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Onyx Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Onyx Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Onyx Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Onyx Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Onyx Pharmaceuticals, Inc., Key Information
  • Onyx Pharmaceuticals, Inc., Key Facts
  • Onyx Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Onyx Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Onyx Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Onyx Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Onyx Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Onyx Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Onyx Pharmaceuticals, Inc. - Pre-Registration, 2015
  • Onyx Pharmaceuticals, Inc. - Phase III, 2015
  • Onyx Pharmaceuticals, Inc. - Phase II, 2015
  • Onyx Pharmaceuticals, Inc. - Phase I, 2015
  • Onyx Pharmaceuticals, Inc. - Preclinical, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Onyx Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Onyx Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Onyx Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Onyx Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Onyx Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Onyx Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Onyx Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top